BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?

BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback raises questions about the mRNA vaccine's prospects in treating pancreatic cancer.